A clinical trial for Novartis AG's Lotrel, a pill that combines two blood pressure drugs, was stopped early because it was shown to reduce heart attacks and strokes 20% more than an ACE inhibitor and diuretic combination. U.S. researchers said the findings may change guidelines for the way hypertension is treated.

Full Story:

Related Summaries